Tags

Type your tag names separated by a space and hit enter

NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.
Curr Opin Investig Drugs. 2009 Jul; 10(7):702-10.CO

Abstract

NeurogesX Inc is developing NGX-4010, a rapid-delivery dermal patch application system that contains high-concentration trans-capsaicin, for the treatment of peripheral neuropathic pain. Capsaicin evokes a lasting and reversible refractory state in primary sensory neurons involved in the generation and maintenance of neuropathic pain. NGX-4010 can be applied to the painful skin area up to a total surface area of 1120 cm2. In phase I clinical trials, NGX-4010 increased the threshold for warmth detection, reduced epidermal sensory nerve fiber density and was well tolerated. In phase II trials, NGX-4010 was effective in reducing pain in patients with post-herpetic neuralgia (PHN), HIV-associated distal sensory neuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). Data from phase III trials in patients with PHN demonstrated that significantly more pain relief was achieved by NGX-4010 (30 to 32% reduction from baseline) compared with a low-concentration capsaicin active control (20 to 24% reduction); however, only one of two studies involving patients with HIV-DSP met the primary endpoint. NGX-4010 appears to have the potential to be an effective adjunctive or a stand-alone therapy for PHN, as well as potentially for HIV-DSP and PDN. NGX-4010 has been granted approval by the European Commission and an NDA has been accepted for filing by the FDA.

Authors+Show Affiliations

Mount Sinai School of Medicine, Department of Anesthesiology, New York, NY 10029, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

19579176

Citation

Noto, Christopher, et al. "NGX-4010, a High-concentration Capsaicin Dermal Patch for Lasting Relief of Peripheral Neuropathic Pain." Current Opinion in Investigational Drugs (London, England : 2000), vol. 10, no. 7, 2009, pp. 702-10.
Noto C, Pappagallo M, Szallasi A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Investig Drugs. 2009;10(7):702-10.
Noto, C., Pappagallo, M., & Szallasi, A. (2009). NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Current Opinion in Investigational Drugs (London, England : 2000), 10(7), 702-10.
Noto C, Pappagallo M, Szallasi A. NGX-4010, a High-concentration Capsaicin Dermal Patch for Lasting Relief of Peripheral Neuropathic Pain. Curr Opin Investig Drugs. 2009;10(7):702-10. PubMed PMID: 19579176.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. AU - Noto,Christopher, AU - Pappagallo,Marco, AU - Szallasi,Arpad, PY - 2009/7/7/entrez PY - 2009/7/7/pubmed PY - 2009/9/23/medline SP - 702 EP - 10 JF - Current opinion in investigational drugs (London, England : 2000) JO - Curr Opin Investig Drugs VL - 10 IS - 7 N2 - NeurogesX Inc is developing NGX-4010, a rapid-delivery dermal patch application system that contains high-concentration trans-capsaicin, for the treatment of peripheral neuropathic pain. Capsaicin evokes a lasting and reversible refractory state in primary sensory neurons involved in the generation and maintenance of neuropathic pain. NGX-4010 can be applied to the painful skin area up to a total surface area of 1120 cm2. In phase I clinical trials, NGX-4010 increased the threshold for warmth detection, reduced epidermal sensory nerve fiber density and was well tolerated. In phase II trials, NGX-4010 was effective in reducing pain in patients with post-herpetic neuralgia (PHN), HIV-associated distal sensory neuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). Data from phase III trials in patients with PHN demonstrated that significantly more pain relief was achieved by NGX-4010 (30 to 32% reduction from baseline) compared with a low-concentration capsaicin active control (20 to 24% reduction); however, only one of two studies involving patients with HIV-DSP met the primary endpoint. NGX-4010 appears to have the potential to be an effective adjunctive or a stand-alone therapy for PHN, as well as potentially for HIV-DSP and PDN. NGX-4010 has been granted approval by the European Commission and an NDA has been accepted for filing by the FDA. SN - 2040-3429 UR - https://www.unboundmedicine.com/medline/citation/19579176/NGX_4010_a_high_concentration_capsaicin_dermal_patch_for_lasting_relief_of_peripheral_neuropathic_pain_ L2 - https://medlineplus.gov/painrelievers.html DB - PRIME DP - Unbound Medicine ER -